Abametapir increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Avoid taking drugs that are CYP3A4 substrates for 2 weeks after using abametapir. If this is not possible, avoid using abametapir.
Amobarbital decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Ethinylestradiol reduces the effect of anastrozole through pharmacodynamic antagonism. Avoid or use alternative medications. Anastrozole should not be co-administered with estrogens or products containing estrogen.
Apalutamide decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Co-administration of apalutamide, a strong CYP3A4 inducer, with medicinal products that are CYP3A4 substrates may result in decreased exposure to these medicinal products. If possible, avoid these drugs or replace them with another drug. Check whether the therapeutic effect is lost when medication has to be administered at the same time. If necessary, adjust the dose according to the prescribing information.
Armodafinil decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
atazanavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .
Belzutifan decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Concomitant use of Belzutifan with hormonal contraceptives may result in contraceptive failure or increased breakthrough bleeding. Advise women of childbearing potential to use effective non-hormonal contraception. According to animal studies, Belzutifan can harm the fetus.
Bosentan decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Brigatinib decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Brigatinib induces CYP3A4 in vitro. Concomitant use of hormonal contraceptives with brigatinib may result in decreased concentrations and loss of efficacy. Brigatinib can harm the fetus. Women should use effective non-hormonal contraception during treatment and for at least 4 months after the last dose of brigatinib.
Butabarbital decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Calaspargase pegol, ethinyl estradiol. unknown mechanism. Avoid or use alternative medications. Due to the possibility of indirect interaction between Calaspargase Pegol and oral contraceptives, the concomitant use of these drugs is not recommended. Use another non-oral contraceptive method in women of childbearing potential.
Ethinylestradiol increases the level or effect of carbamazepine by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.Carbamazepine decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Conivaptan increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Dexamethasone decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Efavirenz decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Ethinyl estradiol reduces the effect of elagolix through pharmacodynamic antagonism. Avoid or use alternative medications. Based on the mechanism of action of elagolix, estrogen-containing contraceptives are expected to reduce the effectiveness of elagolix. The effects of progestogen-only contraceptives on the effectiveness of elagolix are unknown. Recommend women to use non-hormonal contraceptives during treatment with elagolix and for one week after stopping elagolix.
Elvitegravir decreases the level or effect of ethinyl estradiol by an unknown mechanism. Avoid or use alternative medications. Consider alternative non-hormonal contraceptive methods to supplement or replace combined oral contraceptives
Encorafenib decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Co-administration of encorafenib with hormonal contraceptives (CYP3A4 substrates) may result in decreased concentrations and loss of efficacy of hormonal contraceptives. Because encorafenib can cause fetal harm, women of childbearing potential are advised to use a highly effective non-hormonal contraceptive during treatment and for 2 weeks after the last dose of encorafenib.
Ethinylestradiol reduces the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic disease.
Enzalutamide decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Eslicarbazepine acetate decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Use additional or alternative non-hormonal contraceptives.
Ethinylestradiol reduces the effect of exemestane through pharmacodynamic antagonism. Avoid or use alternative medications. Exemestane should not be administered concomitantly with estrogens or products containing estrogen.
Ethinyl estradiol increases the level or effect of fedratinib along with others (see note). Avoid or use alternative medications. Avoid co-administration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitors. The effect of co-administration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied.
Fexinidazole increases the level or effect of ethinyl estradiol by affecting the metabolism of the liver enzyme CYP2E1. Avoid or use alternative medications. Fexinidazole inhibits CYP3A4. Concomitant use may increase the risk of side effects from CYP3A4 substrates.
fosamprenavir, ethinyl estradiol. unspecified interaction mechanism. Avoid or use alternative medications. Co-administration may decrease amprenavir AUC and result in loss of virologic response. Co-administration of fosamprenavir with ethinyl estradiol may alter hormone levels. Alternative methods of non-hormonal contraception are recommended.
Griseofulvin decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Ethinylestradiol reduces the effect of heparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic disease.
Idelalisib increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Idelalisib is a strong CYP3A inhibitor; Avoid co-administration with sensitive CYP3A substrates
indinavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .
Isavuconazonium sulfate increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Ivosidenib decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Avoid co-administration of sensitive CYP3A4 substrates with ivosidenib or substitute alternative therapies. If concomitant use is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
Leniolisib increases the level or effect of ethinyl estradiol along with others (see note). Avoid or use alternative medications. Leniolisib, a BCRP inhibitor, may increase systemic exposure of BCRP substrates
Lesinurad reduces the effect of ethinyl estradiol by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Avoid or use alternative medications. Use additional methods of non-hormonal contraception. Do not rely solely on hormonal contraceptives when taking Lesinurad.
Ethinyl estradiol reduces the effect of letrozole through pharmacodynamic antagonism. Avoid or use alternative medications. Letrozole should not be co-administered with estrogens or products containing estrogen.
Ethinyl estradiol increases the level or effect of lonafarnib by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. If co-administration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce the starting dose or continue treatment with lonafarnib. Monitor carefully for arrhythmias and events (eg, syncope, palpitations) since the effect of lonafarnib on the QT interval is unknown.
lopinavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .Lopinavir increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Lumacaftor/ivacaftor decreases the level or effect of ethinyl estradiol through an unspecified mechanism of interaction. Avoid or use alternative medications. Avoid concomitant use unless the benefits outweigh the risks. With simultaneous use, hormonal contraceptives do not represent a reliable method of effective contraception. Simultaneous use can increase the occurrence of menstrual side effects (amenorrhea, dysmenorrhea, menorrhagia).
Mavacamten decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Progestin and ethinylestradiol are CYP3A4 substrates. Mavacamten may decrease systemic exposure to ethinyl estradiol and progestin, which may result in contraceptive failure or an increase in breakthrough bleeding. Advise patients to use a contraceptive method unaffected by CYP450 enzyme induction (eg, intrauterine system) or non-hormonal contraception (eg, intrauterine system) during concomitant dosing and for 4 months after the last mavacamten dose e.g. condoms).
Ethinyl estradiol reduces the effect of metyrapone through an unspecified mechanism of interaction. Avoid or use alternative medications. A subtherapeutic response to metyrapone may be observed in patients taking estrogens, including oral contraceptives containing estrogen therapy. It may be advisable to discontinue estrogen use before and during metyrapone administration.
Mifepristone increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Mobocertinib decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Concomitant use of mobocertinib with hormonal contraceptives may result in contraceptive failure or increased breakthrough bleeding. Advise women of childbearing potential to use effective non-hormonal contraception.
Mycophenolate reduces the effects of ethinyl estradiol by an unknown mechanism. Avoid or use alternative medications. Patients should consider using an alternative or additional form of contraception.
nelfinavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .Nelfinavir increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Nevirapine decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Omaveloxolone decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Due to the weak CYP3A4 induction, omaveloxolone can reduce the effectiveness of hormonal contraceptives (e.g. pill, patch, ring), implants and progestogen-only pills.
Oxcarbazepine decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Pentobarbital decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Phenobarbital decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Phenytoin decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Primidone decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Quinidine increases the level or effect of ethinyl estradiol through the P-glycoprotein (MDR1) efflux transporter. Avoid or use alternative medications.
Ethinylestradiol increases the level or effect of ranolazine by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Rifabutin decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Rifampicin decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Rifapentine decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
ritonavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .Ritonavir increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
saquinavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .Saquinavir increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications.
Secobarbital decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
St. John's wort decreases the amount or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Sugammadex sodium reduces the effect of ethinylestradiol through receptor binding competition. Avoid or use alternative medications. In vitro binding studies showed that sugammadex can bind to progestin and thus reduce progestin exposure. Therefore, a bolus dose of sugammadex is considered equivalent to one or more missed doses of hormonal contraceptives containing an estrogen or progestogen. If an oral contraceptive is taken on the same day as sugammadex, or if the patient has a transdermal or implanted hormonal contraceptive, the patient must use an additional non-hormonal method of contraception or an additional method of contraception (eg, condoms and spermicides) next 7 to 12 days Dawn.
tipranavir, ethinyl estradiol. Other (see note). Avoid or use alternative medications. Note: Significant changes (increase or decrease) in plasma estrogen levels may occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended. .
Topiramate decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Tucatinib increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Avoid co-administration of tucatinib with CYP3A substrates as minute changes in concentration can result in serious or life-threatening toxicities. If unavoidable, reduce the dose of CYP3A substrate according to product labeling.
Voxelotor increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Avoid or use alternative medications. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid co-administration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of sensitive CYP3A4 substrates if unavoidable.
Ethinyl estradiol reduces the effect of albiglutide through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol increases the level or effect of alosetron by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Ethinyl estradiol increases the level or effect of alprazolam by mechanism: decrease in metabolism. Be careful/monitor. Ethinylestradiol can inhibit the clearance of oxidized benzodiazepines and thus increase the serum concentrations of co-administered benzodiazepines.
Ethinyl estradiol, aminocaproic acid. Other (see note). Be careful/monitor. Note: Concomitant use may result in additive hypercoagulability. Estrogens increase the production of clotting factors and platelet aggregation; Aminocaproic acid inhibits fibrinolysis and the activity of plasminogen.
Amoxicillin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor. Antibiotics can reduce the effectiveness of hormonal birth control.
Ampicillin decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Artemether/Lumefantrine reduces the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinyl estradiol increases the level or effect of atogepant by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Atorvastatin increases the level or effect of ethinyl estradiol through the P-glycoprotein (MDR1) efflux transporter. Be careful/monitor.
Ethinylestradiol increases axitinib levels by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Be careful/monitor.
Ethinyl estradiol increases bendamustine levels by decreasing metabolism. Be careful/monitor. Bendamustine is metabolised to minimally active metabolites by CYP1A2. Ethinylestradiol is a weak inhibitor of CYP1A2 and co-administration may increase bendamustine plasma concentrations. .
Ethinyl estradiol increases caffeine levels or effects by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Cefaclor reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefadroxil decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefazolin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefdinir reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefepime decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefixime decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefotaxime decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefprozil decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ceftazidime decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ceftibuten decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cefuroxime decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cenobamate decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely. If necessary, increase the dose of the CYP3A4 substrate when co-administered with cenobamate.Cenobamate decreases the level or effect of ethinyl estradiol through an unspecified mechanism of interaction. Adjust/monitor therapy closely. Recommend women to use additional or alternative non-hormonal contraception when using cenobamate and oral contraceptives at the same time.
Cephalexin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ceritinib increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Chloramphenicol reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Cimetidine increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ciprofloxacin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Clarithromycin decreases the amount or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Adjust/monitor therapy closely.
Clindamycin decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Clobazam decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. Clobazam is a weak CYP3A4 inducer; The effectiveness of hormonal contraceptives may be reduced when used simultaneously with clobazam. In addition, non-hormonal contraceptive methods are recommended.
Ethinyl estradiol increases the level or effect of clonazepam by mechanism: decrease in metabolism. Be careful/monitor. Ethinylestradiol can inhibit the clearance of oxidized benzodiazepines and thus increase the serum concentrations of co-administered benzodiazepines.
Ethinyl estradiol increases ciclosporin levels by an unknown mechanism. Be careful/monitor.
Dabrafenib decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely.
Darunavir decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely. Significant changes (increase or decrease) in estrogen plasma levels can occur. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Ethinylestradiol increases the level or effect of dasatinib by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Deferasirox decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Demeclocycline reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinyl estradiol increases the level or effect of diazepam by mechanism: decrease in metabolism. Be careful/monitor. Ethinylestradiol can inhibit the clearance of oxidized benzodiazepines and thus increase the serum concentrations of co-administered benzodiazepines.
Dicloxacillin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Doxycycline decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Elagolix reduces the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely. Elagolix is a weak to moderate CYP3A4 inducer. Monitor CYP3A substrates during co-administration. Consider increasing the CYP3A substrate dose if necessary.
Ethinylestradiol increases the level or effect of eltrombopag by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Elvitegravir/cobicistat/emtricitabine/tenofovir DF increases ethinylestradiol levels by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Adjust/monitor therapy closely. Cobicistat is a CYP3A4 inhibitor; Contraindicated with CYP3A4 substrates whose increased plasma concentrations are associated with serious and/or life-threatening events.
Encorafenib increases the level or effect of ethinyl estradiol along with others (see note). Adjust/monitor therapy closely. Encorafenib (a BCRP inhibitor) can increase the concentration and toxicity of BCRP substrates. Monitor closely for signs and symptoms of increased exposure and consider dose adjustments of these substrates.
Erythromycin base reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor. Antibiotics can reduce the effectiveness of hormonal birth control.
Erythromycin ethyl succinate decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor. Antibiotics can reduce the effectiveness of hormonal birth control.
Erythromycin lactobionate decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor. Antibiotics can reduce the effectiveness of hormonal birth control.
Erythromycin stearate decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor. Antibiotics can reduce the effectiveness of hormonal birth control.
Etravirine decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Be careful/monitor. The effectiveness of hormonal contraceptives may be reduced. The use of a non-hormonal contraceptive is recommended.
Ethinyl estradiol, exenatide solution for injection. Other (see note). Be careful/monitor. Note: Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Exenatide's effect on delaying gastric emptying may decrease the volume and rate of oral drugs that require rapid gastrointestinal absorption. Recommend patients to take oral contraceptives at least 1 hour before exenatide. .
Ethinyl estradiol, exenatide injectable suspension. Other (see note). Be careful/monitor. Note: Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Exenatide's effect on delaying gastric emptying may decrease the volume and rate of oral drugs that require rapid gastrointestinal absorption. Recommend patients to take oral contraceptives at least 1 hour before exenatide.
Fedratinib increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. If necessary, adjust the dosage of drugs that are CYP3A4 substrates.
Ethinyl estradiol increases the level or effect of finerenone by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely. Monitor serum potassium levels during initiation and dose adjustment of fineerone or weak CYP3A4 inhibitors. Adjust the fineerone dose if necessary.
Ethinyl estradiol increases the level or effect of flibanserin by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. Additional side effects of flibanserin may occur when used concomitantly with multiple weak CYP3A4 inhibitors.
Fluconazole increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinylestradiol increases the level or effect of fluvoxamine by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Fostemsavir increases the level or effect of ethinylestradiol together with others (see Note). Adjust/monitor therapy closely. Fostemsavir inhibits BCRP transporters. If possible, avoid co-administration or adjust the dose of BCRP substrate co-administered with fostemsavir. The dosage of ethinyl estradiol should not exceed 30 µg/day.
Gemifloxacin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Grapefruit increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinyl estradiol increases green tea levels by reducing its elimination. Be careful/monitor.
Ethinylestradiol reduces the action of hemin through pharmacodynamic antagonism. Be careful/monitor. Drugs that increase delta-aminolevulinic acid synthetase may decrease hemin effects.
Ethinyl estradiol reduces the action of hyaluronidase by others (see note). Be careful/monitor. Note: Estrogens, when administered in large systemic doses, can render tissues partially resistant to the effects of hyaluronidase. Patients may require higher levels of hyaluronidase to achieve an equivalent dispersing effect.
Iloperidone increases ethinylestradiol levels by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Be careful/monitor. Iloperidone is a time-dependent CYP3A inhibitor and can lead to increased plasma levels of drugs that are mainly eliminated by CYP3A4.
Ethinylestradiol reduces the action of insulin aspart through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol reduces the effect of insulin degludec through pharmacodynamic antagonism. Be careful/monitor. Estrogens can impair glucose tolerance.
Ethinylestradiol reduces the effect of insulin degludec/insulin aspart through pharmacodynamic antagonism. Be careful/monitor. Estrogens can impair glucose tolerance.
Ethinylestradiol reduces the effect of insulin detemir through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol reduces the effect of insulin glargine through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol reduces the effect of insulin glulisine through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol reduces the effect of inhaled insulin through pharmacodynamic antagonism. Be careful/monitor. Estrogens can impair glucose tolerance.
Ethinyl estradiol reduces the effect of insulin lispro through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol reduces the action of insulin NPH through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol reduces the effect of regular human insulin through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Ethinylestradiol increases the level or effect of isavuconazonium sulfate by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Istradefylline increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical studies. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
Itraconazole increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. CYP3A4 inhibitors such as itraconazole may increase plasma levels of the hormone.
Ketoconazole increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. CYP3A4 inhibitors such as ketoconazole can increase plasma hormone levels.
Ethinylestradiol decreases lamotrigine levels by increasing hepatic clearance. Be careful/monitor. COCs have been shown to significantly decrease lamotrigine plasma concentrations, probably due to induction of lamotrigine glucuronidation.
Ethinylestradiol increases the level or effect of lapatinib by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinyl estradiol increases the level or effect of lemborexant by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely. A lower nocturnal dose of lemborexant is recommended when co-administered with weak CYP3A4 inhibitors. See drug monograph for specific dosage adjustments.
Lenacapavir increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates started within 9 months of the last subcutaneous dose of lenacapavir, which may increase the potential risk of CYP3A4 substrate adverse reactions.
Levofloxacin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Levoketoconazole increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. CYP3A4 inhibitors such as ketoconazole can increase plasma hormone levels.
Ethinyl estradiol reduces the effect of liraglutide through pharmacodynamic antagonism. Be careful/monitor. Oral contraceptives can reduce the hypoglycaemic effect of antidiabetic drugs by impairing glucose tolerance. Monitoring of glycemic control in diabetics.
Lixisenatide (DSC) decreases the level or effect of ethinylestradiol by inhibiting gastrointestinal absorption. Applies only to the oral form of both drugs. Adjust/monitor therapy closely. GLP1 agonists delay gastric emptying, which may impair the absorption of concomitant oral drugs. Oral contraceptives should be taken at least 1 hour before lixisenatide administration or 11 hours after lixisenatide administration.
Ethinyl estradiol increases lomitapide levels by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Be careful/monitor. The dose of lomitapide should not exceed 30 mg/day.
Ethinyl estradiol decreases the level or effect of lonapegsomatropin with other medicines (see note). Be careful/monitor. Oral estrogens may decrease the serum insulin-like growth factor-1 response to lonapegsomatropin. Patients receiving oral estrogen replacement may require higher doses of lonapegsomatropin.
Lorlatinib decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Lumefantrine decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinylestradiol reduces the effect of metformin through pharmacodynamic antagonism. Be careful/monitor.
Metronidazole decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinyl estradiol increases the level or effect of mexiletine by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Ethinyl estradiol increases the level or effect of midazolam by mechanism: decrease in metabolism. Be careful/monitor. Ethinylestradiol can inhibit the clearance of oxidized benzodiazepines and thus increase the serum concentrations of co-administered benzodiazepines.
Ethinyl estradiol increases the level or effect of intranasal midazolam by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Be careful/monitor. Concomitant use of mild CYP3A4 inhibitors with intranasal midazolam may increase systemic exposure to midazolam, which may prolong sedation.
Mifepristone reduces the effect of ethinyl estradiol through pharmacodynamic antagonism. Be careful/monitor. An additional method of contraception is recommended.
Minocycline decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Mitotane lowers ethinylestradiol levels by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. Mitotane is a potent inducer of cytochrome P-4503A4; Be aware of possible dose adjustments when co-administered with CYP3A4 substrates.
Moxifloxacin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Nafcillin decreases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Neomycin PO decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinyl estradiol increases the level or effect of nicardipine by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinylestradiol increases the level or effect of nilotinib by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Nirmatrelvir decreases the level or effect of ethinyl estradiol by increasing its metabolism. Adjust/monitor therapy closely. Consider using an additional non-hormonal method of birth control for the remainder of the cycle. Mechanism unknown but possibly due to ritonavir CYP2C9 or CYP1A2 induction.
Nirmatrelvir/ritonavir decreases the level or effect of ethinyl estradiol by increasing its metabolism. Adjust/monitor therapy closely. Consider using an additional non-hormonal method of birth control for the remainder of the cycle. Mechanism unknown but possibly due to ritonavir CYP2C9 or CYP1A2 induction.
Nitrofurantoin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ofloxacin decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinylestradiol increases the level or effect of olanzapine by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Oteseconazole increases the level or effect of ethinyl estradiol along with others (see note). Adjust/monitor therapy closely. Otesezonale, a BCRP inhibitor, may increase the effect and risk of toxicity of BCRP substrates. Use the lowest starting dose of BCRP substrate or consider reducing the BCRP substrate dose.
Paromomycin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Penicillin G in aqueous solution lowers ethinyl estradiol levels by stimulating metabolism. Be careful/monitor. Risk of oral contraceptive failure.
Penicillin VK reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Pioglitazone lowers ethinyl estradiol levels by an unknown mechanism. Be careful/monitor.
Posaconazole increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Quinupristin/Dalfopristin increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinyl estradiol increases the level or effect of ramelteon by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Ethinyl estradiol increases the level or effect of rasagiline by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor. The recommended dose of rasagiline is 0.5 mg per day in combination with CYP1A2 inhibitors.
Ribociclib increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Romidepsin reduces the effect of ethinyl estradiol through receptor binding competition. Be careful/monitor.
Ethinylestradiol increases the level or effect of ropinirole by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.Ethinyl estradiol increases ropinirole levels through an unspecified mechanism of interaction. Be careful/monitor.
Rucaparib increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Adjust/monitor therapy closely. Adjust the dosage of CYP3A4 substrates according to the clinical indication.
Rufinamide reduces the effect of ethinyl estradiol by affecting CYP3A4 metabolism in the hepatic/intestinal enzymes. Be careful/monitor. Rufinamide is a weak inducer of the CYP3A4 enzyme and may decrease exposure to medicinal products that are substrates of CYP3A4. .
Ethinyl estradiol increases selegiline levels along with others (see comment). Be careful/monitor. Note: Oral contraceptives inhibit selegiline's N-demethylatin.
Ethinyl estradiol increases transdermal selegiline levels by others (see comment). Be careful/monitor. Note: Oral contraceptives inhibit selegiline's N-demethylatin.
siltuximab, ethinyl estradiol. Other (see note). Be careful/monitor. Note: CYP450 activity in the liver is downregulated by infectious and inflammatory stimuli, including cytokines (e.g. IL-6); IL-6 inhibition by siltuximab may restore CYP450 enzymatic activity; Caution should be exercised when co-administered with CYP substrates with a narrow therapeutic index.
stiripentol, ethinyl estradiol. Impaired CYP3A4 metabolism in the liver/intestinal enzymes. Adjust/monitor therapy closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates co-administered with stiripentol for increased or decreased effects. Dose adjustment may be required for CYP3A4 substrates.
Sulfadiazine decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Sulfamethoxazole decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Sulfisoxazole decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinyl estradiol increases the level or effect of tacrolimus by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Tazemetostat decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.Ethinyl estradiol increases the level or effect of tazemetostat by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Tecovirimat decreases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for efficacy with co-administration.
Teriflunomide increases ethinyl estradiol levels by an unknown mechanism. Be careful/monitor.
Tetracycline decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinyl estradiol increases the level or effect of theophylline by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor.
Ticarcillin reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Tigecycline reduces the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinyl estradiol increases the level or effect of tinidazole by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinyl estradiol increases the level or effect of tizanidine by affecting the metabolism of the liver enzyme CYP1A2. Be careful/monitor. Check for side effects (eg, hypotension or bradycardia) with tizanidine.
Ethinyl estradiol increases the level or effect of tolterodine by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Ethinyl estradiol increases the level or effect of triazolam by mechanism: decrease in metabolism. Be careful/monitor. Ethinylestradiol can inhibit the clearance of oxidized benzodiazepines and thus increase the serum concentrations of co-administered benzodiazepines.
Trimethoprim decreases the level or effect of ethinyl estradiol by altering the gut flora. Applies only to oral forms of hormones. Low risk of contraceptive failure. Be careful/monitor.
Ethinylestradiol reduces the effect of ursodiol through pharmacodynamic antagonism. Be careful/monitor.
Ethinyl estradiol decreases the level or effect of valproic acid by increasing its elimination. Adjust/monitor therapy closely. Can lead to increased attack frequency
Voriconazole increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. Be careful/monitor.
Acetazolamide increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
ethinyl estradiol, amitriptyline. Mechanism: unspecified interaction mechanism. minor/meaning unknown. Estrogens and progestins may decrease the tricyclic antidepressant effect while increasing TCA plasma concentrations and side effects.
ethinyl estradiol, amoxapine. Mechanism: unspecified interaction mechanism. minor/meaning unknown. Estrogens and progestins may decrease the tricyclic antidepressant effect while increasing TCA plasma concentrations and side effects.
Anastrozole increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Ethinylestradiol increases the level or effect of antipyrine by affecting the metabolism of the liver enzyme CYP1A2. minor/meaning unknown.
Ethinylestradiol increases the level or effect of asenapine by affecting the metabolism of the liver enzyme CYP1A2. minor/meaning unknown.
Ethinylestradiol increases the level or effect of clarithromycin by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Ethinylestradiol increases the level or effect of clomipramine by affecting the metabolism of the liver enzyme CYP1A2. minor/meaning unknown.
Cyclophosphamide increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
ethinyl estradiol, desipramine. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
ethinyl estradiol, dosulepin. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
ethinyl estradiol, doxepin. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
Ethinyl estradiol increases the level or effect of duloxetine by affecting the metabolism of the liver enzyme CYP1A2. minor/meaning unknown.
enasidenib, ethinyl estradiol. unknown mechanism. minor/meaning unknown. Concomitant use of enasidenib may increase or decrease concentrations of combined hormonal contraceptives. The clinical significance of this interaction is unknown.
Ethinyl estradiol increases the level or effect of eplerenone by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Felbamate lowers ethinyl estradiol levels by an unknown mechanism. minor/meaning unknown.
Ethinyl estradiol increases the level or effect of frovatriptan by affecting the metabolism of the liver enzyme CYP1A2. minor/meaning unknown.
ethinyl estradiol, imipramine. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
Larotrectinib increases the level or effect of ethinyl estradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Mineral oil lowers ethinylestradiol levels by inhibiting gastrointestinal absorption. Applies only to the oral form of both drugs. minor/meaning unknown.
Ethinyl estradiol potentiates the effects of naratriptan through an unspecified mechanism of interaction. minor/meaning unknown. The clinical implications of these interactions are unknown.
Nefazodone increases the level or effect of ethinylestradiol by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
ethinyl estradiol, nortriptyline. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
ethinyl estradiol, protriptyline. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
Ethinylestradiol increases the level or effect of ramelteon by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Rosuvastatin increases ethinylestradiol levels through an unspecified mechanism of interaction. minor/meaning unknown.
Ethinyl estradiol increases the level or effect of ruxolitinib by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Ethinyl estradiol increases the level or effect of topical ruxolitinib by affecting CYP3A4 metabolism in the liver/gut enzymes. minor/meaning unknown.
Ethinyl estradiol increases tizanidine levels through an unspecified mechanism of interaction. minor/meaning unknown.
ethinyl estradiol, trazodone. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.
ethinyl estradiol, trimipramine. Mechanism: unspecified interaction mechanism. minor/meaning unknown. The oxidative metabolism of TCAs can be reduced by ethinylestradiol. Increased serum concentrations of antidepressants may occur. Possible increased TCA side effects.